268 related articles for article (PubMed ID: 22185350)
1. Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.
Hassan MK; Watari H; Han Y; Mitamura T; Hosaka M; Wang L; Tanaka S; Sakuragi N
J Exp Clin Cancer Res; 2011 Dec; 30(1):113. PubMed ID: 22185350
[TBL] [Abstract][Full Text] [Related]
2. Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel.
Hassan MK; Watari H; Christenson L; Bettuzzi S; Sakuragi N
Tumour Biol; 2011 Oct; 32(5):1031-47. PubMed ID: 21761117
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.
So A; Sinnemann S; Huntsman D; Fazli L; Gleave M
Mol Cancer Ther; 2005 Dec; 4(12):1837-49. PubMed ID: 16373699
[TBL] [Abstract][Full Text] [Related]
4. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer.
Park DC; Yeo SG; Wilson MR; Yerbury JJ; Kwong J; Welch WR; Choi YK; Birrer MJ; Mok SC; Wong KK
Neoplasia; 2008 Sep; 10(9):964-72. PubMed ID: 18714397
[TBL] [Abstract][Full Text] [Related]
5. Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer.
Wei L; Xue T; Wang J; Chen B; Lei Y; Huang Y; Wang H; Xin X
Int J Cancer; 2009 Aug; 125(4):791-806. PubMed ID: 19391138
[TBL] [Abstract][Full Text] [Related]
6. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J.
Lourda M; Trougakos IP; Gonos ES
Int J Cancer; 2007 Feb; 120(3):611-22. PubMed ID: 17096323
[TBL] [Abstract][Full Text] [Related]
7. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.
Lamoureux F; Baud'huin M; Ory B; Guiho R; Zoubeidi A; Gleave M; Heymann D; Rédini F
Oncotarget; 2014 Sep; 5(17):7805-19. PubMed ID: 25138053
[TBL] [Abstract][Full Text] [Related]
8. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract][Full Text] [Related]
9. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of clusterin expression in advanced-stage cervical cancer treated with curative intended radiotherapy.
Watari H; Kinoshita R; Han Y; Wang L; Hosaka M; Taguchi H; Tsuchiya K; Tanaka S; Shirato H; Sakuragi N
Int J Gynecol Cancer; 2012 Mar; 22(3):465-70. PubMed ID: 21633299
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer.
Fu Y; Lai Y; Wang Q; Liu X; He W; Zhang H; Fan C; Yang G
Mol Med Rep; 2013 Jun; 7(6):1726-32. PubMed ID: 23616046
[TBL] [Abstract][Full Text] [Related]
12. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
Jiang J; Wang S; Wang Z; Cai J; Han L; Xie L; Han Q; Wang W; Zhang Y; He X; Yang C
Cancer Chemother Pharmacol; 2020 Aug; 86(2):295-305. PubMed ID: 32743678
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
[TBL] [Abstract][Full Text] [Related]
14. Clusterin (CLU) and lung cancer.
Panico F; Rizzi F; Fabbri LM; Bettuzzi S; Luppi F
Adv Cancer Res; 2009; 105():63-76. PubMed ID: 19879423
[TBL] [Abstract][Full Text] [Related]
15. Clusterin confers paclitaxel resistance in cervical cancer.
Park DC; Yeo SG; Shin EY; Mok SC; Kim DH
Gynecol Oncol; 2006 Dec; 103(3):996-1000. PubMed ID: 16890274
[TBL] [Abstract][Full Text] [Related]
16. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
17. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
Yang H; Mao W; Rodriguez-Aguayo C; Mangala LS; Bartholomeusz G; Iles LR; Jennings NB; Ahmed AA; Sood AK; Lopez-Berestein G; Lu Z; Bast RC
Clin Cancer Res; 2018 Oct; 24(20):5072-5084. PubMed ID: 30084832
[No Abstract] [Full Text] [Related]
19. Knockdown of clusterin expression increases the in vitro sensitivity of human prostate cancer cells to paclitaxel.
Chun YJ
J Toxicol Environ Health A; 2014; 77(22-24):1443-50. PubMed ID: 25343293
[TBL] [Abstract][Full Text] [Related]
20. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
